About: Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19
Creator	Brennan, Peter Rao, Vishal Arakeri, Gururaj Jadhav, Sachin Rao, Gururaj Rao, Jyothsna Sayeed, Suhail Mds, Gururaj Thakur, Shalini
source	Elsevier; Medline; PMC; WHO
abstract	Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14 - 20 days,. However, about 15 % of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (< 65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.109845
bibo:pmid	32425307
has license	no-cc
sha1sum (hex)	5fa2c320aec12f1901a17adf7b8e03c8eb0b017a
schema:url	https://doi.org/10.1016/j.mehy.2020.109845
resource representing a document's title	Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19
has PubMed Central identifier	PMC7232064
has PubMed identifier	32425307
schema:publication	Med Hypotheses
resource representing a document's body	covid:5fa2c320aec12f1901a17adf7b8e03c8eb0b017a#body_text
is schema:about of	named entity 'patients' named entity 'virus' named entity 'ABOUT' named entity 'mild' named entity 'severe' named entity 'infected' named entity 'COVID' named entity 'clinical trial' named entity 'co-morbidities' named entity 'IFN-γ' named entity 'viral replication' named entity 'adaptive immune cells' named entity 'innate immune response' named entity 'MSCs' named entity 'antiviral' named entity 'adaptive immunity' named entity 'Interferon-alpha' named entity 'effector' named entity 'CD4+ cell' named entity 'TGF' named entity 'hyaline' named entity 'Th1 cells' named entity 'TH17' named entity 'IgM' named entity 'dental pulp' named entity 'virus' named entity 'lung parenchyma' named entity 'MSCs' named entity 'autoimmune disorders' named entity 'virus' named entity 'bone marrow' named entity 'CD8 T cells' named entity 'cell lines' named entity 'infection' named entity 'T cell' named entity 'acute respiratory distress syndrome' named entity 'COVID' named entity 'COVID' named entity 'CD8+' named entity 'inflammatory responses' named entity 'lung injury' named entity 'Nitric oxide' named entity 'IFN-gamma' named entity 'COVID' named entity 'COVID' named entity 'MHC' named entity 'IFN' named entity 'virus' named entity 'lung' named entity 'lungs' named entity 'adaptive immune' named entity 'IL1' named entity 'IL6' named entity 'cytotoxic T cells' named entity 'TH1' named entity 'lysed' named entity 'transfusion' named entity 'Transforming growth factor' named entity 'TNF alpha' named entity 'Th1' named entity 'immune response' named entity 'co-expression' named entity 'mesenchymal stem cells' named entity 'COVID' named entity 'ARDS' named entity 'elderly age' named entity 'CD38' named entity 'TNF alpha' named entity 'CD4' named entity 'pro-inflammatory' named entity 'cytokine storm' named entity 'MSCs' named entity 'interleukin 6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software